Cargando…

Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma

BACKGROUND: Xp11.2 or TFE3 translocation renal cell carcinomas (RCC) and alveolar soft part sarcoma (ASPS) are characterized by chromosome translocations involving the Xp11.2 breakpoint resulting in transcription factor TFE3 gene fusions. The most common translocations documented in TFE3 RCCs are t(...

Descripción completa

Detalles Bibliográficos
Autores principales: Pradhan, Dinesh, Roy, Somak, Quiroga-Garza, Gabriela, Cieply, Kathleen, Mahaffey, Alyssa L., Bastacky, Sheldon, Dhir, Rajiv, Parwani, Anil V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4587681/
https://www.ncbi.nlm.nih.gov/pubmed/26415891
http://dx.doi.org/10.1186/s13000-015-0412-z
_version_ 1782392500441317376
author Pradhan, Dinesh
Roy, Somak
Quiroga-Garza, Gabriela
Cieply, Kathleen
Mahaffey, Alyssa L.
Bastacky, Sheldon
Dhir, Rajiv
Parwani, Anil V.
author_facet Pradhan, Dinesh
Roy, Somak
Quiroga-Garza, Gabriela
Cieply, Kathleen
Mahaffey, Alyssa L.
Bastacky, Sheldon
Dhir, Rajiv
Parwani, Anil V.
author_sort Pradhan, Dinesh
collection PubMed
description BACKGROUND: Xp11.2 or TFE3 translocation renal cell carcinomas (RCC) and alveolar soft part sarcoma (ASPS) are characterized by chromosome translocations involving the Xp11.2 breakpoint resulting in transcription factor TFE3 gene fusions. The most common translocations documented in TFE3 RCCs are t(X;1) (p11.2;q21) and t(X;17) (p11.2;q25) which leads to fusion of TFE3 gene on Xp11.2 with PRCC or ASPL respectively. TFE3 immunohistochemistry (IHC) has been inconsistent over time due to background staining problems in part related to fixation issues. Karyotyping to detect TFE3 gene rearrangement requires typically unavailable fresh tissue. Reverse transcriptase-polymerase chain reaction (RT-PCR) is generally very challenging due to degradation of RNA in archival material. The study objective was to develop and validate a TFE3 break-apart fluorescence in situ hybridization (FISH) assay to confirm Xp11 translocation RCCs and ASPS. METHODS: Representative sections of formalin-fixed paraffin-embedded tissue blocks were selected in 40 possible cases. Approximately 60 tumor cells were analyzed in the targeted region. The validation of TFE3 FISH was done with 11 negative and two positive cases. Cut off for a positive result was validated as >7.15 % positive nuclei with any pattern of break-apart signals. FISH evaluation was done blinded of the immunohistochemical or karyotype data. RESULTS: Three out of forty cases were positive for the TFE3 break-apart signals by FISH. The negative cases were reported as clear cell RCC with papillary features (10), clear cell RCC with sarcomatoid areas (2), Papillary RCC with clear cell areas (9), Chromophobe RCC (2), RCC, unclassified type (3) and renal medullary carcinoma (1). 3 of the negative cases were consultation cases for renal tumor with unknown histology. Seven negative cases were soft tissue tumor suspicious for ASPS. CONCLUSION: Our study validates the utility of TFE3 break-apart FISH on formalin-fixed paraffin-embedded tissue sections for diagnosis and confirmation of Xp11.2 translocation RCCs and ASPS.
format Online
Article
Text
id pubmed-4587681
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45876812015-09-30 Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma Pradhan, Dinesh Roy, Somak Quiroga-Garza, Gabriela Cieply, Kathleen Mahaffey, Alyssa L. Bastacky, Sheldon Dhir, Rajiv Parwani, Anil V. Diagn Pathol Research BACKGROUND: Xp11.2 or TFE3 translocation renal cell carcinomas (RCC) and alveolar soft part sarcoma (ASPS) are characterized by chromosome translocations involving the Xp11.2 breakpoint resulting in transcription factor TFE3 gene fusions. The most common translocations documented in TFE3 RCCs are t(X;1) (p11.2;q21) and t(X;17) (p11.2;q25) which leads to fusion of TFE3 gene on Xp11.2 with PRCC or ASPL respectively. TFE3 immunohistochemistry (IHC) has been inconsistent over time due to background staining problems in part related to fixation issues. Karyotyping to detect TFE3 gene rearrangement requires typically unavailable fresh tissue. Reverse transcriptase-polymerase chain reaction (RT-PCR) is generally very challenging due to degradation of RNA in archival material. The study objective was to develop and validate a TFE3 break-apart fluorescence in situ hybridization (FISH) assay to confirm Xp11 translocation RCCs and ASPS. METHODS: Representative sections of formalin-fixed paraffin-embedded tissue blocks were selected in 40 possible cases. Approximately 60 tumor cells were analyzed in the targeted region. The validation of TFE3 FISH was done with 11 negative and two positive cases. Cut off for a positive result was validated as >7.15 % positive nuclei with any pattern of break-apart signals. FISH evaluation was done blinded of the immunohistochemical or karyotype data. RESULTS: Three out of forty cases were positive for the TFE3 break-apart signals by FISH. The negative cases were reported as clear cell RCC with papillary features (10), clear cell RCC with sarcomatoid areas (2), Papillary RCC with clear cell areas (9), Chromophobe RCC (2), RCC, unclassified type (3) and renal medullary carcinoma (1). 3 of the negative cases were consultation cases for renal tumor with unknown histology. Seven negative cases were soft tissue tumor suspicious for ASPS. CONCLUSION: Our study validates the utility of TFE3 break-apart FISH on formalin-fixed paraffin-embedded tissue sections for diagnosis and confirmation of Xp11.2 translocation RCCs and ASPS. BioMed Central 2015-09-29 /pmc/articles/PMC4587681/ /pubmed/26415891 http://dx.doi.org/10.1186/s13000-015-0412-z Text en © Pradhan et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Pradhan, Dinesh
Roy, Somak
Quiroga-Garza, Gabriela
Cieply, Kathleen
Mahaffey, Alyssa L.
Bastacky, Sheldon
Dhir, Rajiv
Parwani, Anil V.
Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma
title Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma
title_full Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma
title_fullStr Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma
title_full_unstemmed Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma
title_short Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma
title_sort validation and utilization of a tfe3 break-apart fish assay for xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4587681/
https://www.ncbi.nlm.nih.gov/pubmed/26415891
http://dx.doi.org/10.1186/s13000-015-0412-z
work_keys_str_mv AT pradhandinesh validationandutilizationofatfe3breakapartfishassayforxp112translocationrenalcellcarcinomaandalveolarsoftpartsarcoma
AT roysomak validationandutilizationofatfe3breakapartfishassayforxp112translocationrenalcellcarcinomaandalveolarsoftpartsarcoma
AT quirogagarzagabriela validationandutilizationofatfe3breakapartfishassayforxp112translocationrenalcellcarcinomaandalveolarsoftpartsarcoma
AT cieplykathleen validationandutilizationofatfe3breakapartfishassayforxp112translocationrenalcellcarcinomaandalveolarsoftpartsarcoma
AT mahaffeyalyssal validationandutilizationofatfe3breakapartfishassayforxp112translocationrenalcellcarcinomaandalveolarsoftpartsarcoma
AT bastackysheldon validationandutilizationofatfe3breakapartfishassayforxp112translocationrenalcellcarcinomaandalveolarsoftpartsarcoma
AT dhirrajiv validationandutilizationofatfe3breakapartfishassayforxp112translocationrenalcellcarcinomaandalveolarsoftpartsarcoma
AT parwanianilv validationandutilizationofatfe3breakapartfishassayforxp112translocationrenalcellcarcinomaandalveolarsoftpartsarcoma